A5073800105- Blood Pressure and Hypertension Studies
- Hormonal Regulation and Hypertension
- Sodium Intake and Health
- Renal and Vascular Pathologies
- Heart Rate Variability and Autonomic Control
- Cardiovascular Syncope and Autonomic Disorders
- Diabetes Treatment and Management
- Nutritional Studies and Diet
- Chronic Kidney Disease and Diabetes
- Dialysis and Renal Disease Management
- Hemodynamic Monitoring and Therapy
- Cardiovascular Health and Disease Prevention
- Pharmaceutical Practices and Patient Outcomes
- Pharmacology and Obesity Treatment
- Cardiac, Anesthesia and Surgical Outcomes
- Heart Failure Treatment and Management
- Heart rate and cardiovascular health
- Health Systems, Economic Evaluations, Quality of Life
- Cardiovascular Health and Risk Factors
- Renin-Angiotensin System Studies
- Diet and metabolism studies
- Cerebrovascular and Carotid Artery Diseases
- Aortic aneurysm repair treatments
- Advanced X-ray and CT Imaging
- Global Health Care Issues
University of Michigan
2015-2024
Michigan Medicine
2011-2024
American College of Preventive Medicine
2017-2018
Minneapolis Institute of Arts
2016-2018
Rhode Island Hospital
2016
Brown University
2007-2016
University Health System
2016
Ann Arbor VA Medical Center
1995-2015
SUNY Downstate Health Sciences University
2010-2013
Society of Interventional Radiology
2013
The optimal combination drug therapy for hypertension is not established, although current U.S. guidelines recommend inclusion of a diuretic. We hypothesized that treatment with the an angiotensin-converting-enzyme (ACE) inhibitor and dihydropyridine calcium-channel blocker would be more effective in reducing rate cardiovascular events than ACE plus thiazide diuretic.In randomized, double-blind trial, we assigned 11,506 patients who were at high risk to receive either benazepril amlodipine...
Atherosclerotic renal-artery stenosis is a common problem in the elderly. Despite two randomized trials that did not show benefit of stenting with respect to kidney function, usefulness for prevention major adverse renal and cardiovascular events uncertain.We randomly assigned 947 participants who had atherosclerotic either systolic hypertension while taking or more antihypertensive drugs chronic disease medical therapy plus alone. Participants were followed occurrence (a composite end point...
In observational studies, the relationship between blood pressure and end-stage renal disease (ESRD) is direct progressive. The burden of hypertension-related chronic kidney ESRD especially high among black patients. Yet few trials have tested whether intensive blood-pressure control retards progression
Insights into end-stage renal disease have emerged from many investigations but less is known about the epidemiology of chronic insufficiency (CRI) and its relationship to cardiovascular (CVD). The Chronic Renal Insufficiency Cohort (CRIC) Study was established examine risk factors for progression CRI CVD among patients develop models identify high-risk subgroups, informing future treatment trials, increasing application preventive therapies. CRIC will enroll approximately 3000 individuals...
Abstract. This article reports further analyses of the Hypertension Optimal Treatment (HOT) Study data with aim to describe ( 1 ) value baseline serum creatinine and its clearance (estimated by Cockroft Gault formula) as predictors cardiovascular events, 2 effects intensive lowering BP on events renal function in patients reduced function, 3 adding acetylsalicylic acid antihypertensive therapy function. The results show that elevation a reduction estimated are powerful death. Reduced at did...
In the short term, endothelin antagonist avosentan reduces proteinuria, but whether this translates to protection from progressive loss of renal function is unknown. We examined effects on progression overt diabetic nephropathy in a multicenter, multinational, double-blind, placebo-controlled trial. randomly assigned 1392 participants with type 2 diabetes oral (25 or 50 mg) placebo addition continued angiotensin-converting enzyme inhibition and/or angiotensin receptor blockade. The composite...
Since the first International Society on Hypertension in Blacks consensus statement “Management of High Blood Pressure African American” 2003, data from additional clinical trials have become available. We reviewed hypertension and cardiovascular disease prevention treatment guidelines, pharmacological end point trials, blood pressure–lowering blacks. Selected without significant black representation were considered. In this update, blacks with are divided into 2 risk strata, primary...
Inferences about the association between sympathetic overactivity and insulin resistance have been drawn from infusion of sympathomimetic amines in supraphysiological doses. We used isolated perfused human forearm to investigate effect reflex-induced nervous system activation on peripheral utilization glucose skeletal muscles 14 healthy men. Local hyperinsulinemia (132 +/- 25 microunits/mL for 90 minutes) induced a significant increase baseline (16.4 3.1 mg.dL-1.min-1 per 100 mL volume)...
Context Type 2 diabetes is emerging as a major health problem, which tends to cluster with hypertension in individuals at high risk of cardiovascular disease. Objective To test for the first time hypothesis that treatment hypertensive patients angiotensin-receptor blocker (ARB) valsartan prevents new-onset type compared metabolically neutral calcium-channel antagonist (CCA) amlodipine. Design Pre-specified analysis VALUE trial. Follow-up averaged 4.2 years. The developing new was calculated...